Literature DB >> 28087820

Emerging functional roles of nuclear receptors in breast cancer.

Tram B Doan1, J Dinny Graham2, Christine L Clarke2.   

Abstract

Nuclear receptors (NRs) have been targets of intensive drug development for decades due to their roles as key regulators of multiple developmental, physiological and disease processes. In breast cancer, expression of the estrogen and progesterone receptor remains clinically important in predicting prognosis and determining therapeutic strategies. More recently, there is growing evidence supporting the involvement of multiple nuclear receptors other than the estrogen and progesterone receptors, in the regulation of various processes important to the initiation and progression of breast cancer. We review new insights into the mechanisms of action of NRs made possible by recent advances in genomic technologies and focus on the emerging functional roles of NRs in breast cancer biology, including their involvement in circadian regulation, metabolic reprogramming and breast cancer migration and metastasis.
© 2017 Society for Endocrinology.

Entities:  

Keywords:  breast cancer; circadian clock; metabolism; migration and metastasis; nuclear receptors

Mesh:

Substances:

Year:  2017        PMID: 28087820     DOI: 10.1530/JME-16-0082

Source DB:  PubMed          Journal:  J Mol Endocrinol        ISSN: 0952-5041            Impact factor:   5.098


  10 in total

1.  Interferon-Stimulated Genes Are Transcriptionally Repressed by PR in Breast Cancer.

Authors:  Katherine R Walter; Merit L Goodman; Hari Singhal; Jade A Hall; Tianbao Li; Sean M Holloran; Gloria M Trinca; Katelin A Gibson; Victor X Jin; Geoffrey L Greene; Christy R Hagan
Journal:  Mol Cancer Res       Date:  2017-07-06       Impact factor: 5.852

Review 2.  Higher order genomic organization and epigenetic control maintain cellular identity and prevent breast cancer.

Authors:  A J Fritz; N E Gillis; D L Gerrard; P D Rodriguez; D Hong; J T Rose; P N Ghule; E L Bolf; J A Gordon; C E Tye; J R Boyd; K M Tracy; J A Nickerson; A J van Wijnen; A N Imbalzano; J L Heath; S E Frietze; S K Zaidi; F E Carr; J B Lian; J L Stein; G S Stein
Journal:  Genes Chromosomes Cancer       Date:  2019-03-15       Impact factor: 5.006

Review 3.  TLX, an Orphan Nuclear Receptor With Emerging Roles in Physiology and Disease.

Authors:  Adam T Nelson; Yu Wang; Erik R Nelson
Journal:  Endocrinology       Date:  2021-11-01       Impact factor: 5.051

4.  Considering hormone-sensitive cancers as a single disease in the UK biobank reveals shared aetiology.

Authors:  Muktar Ahmed; Ville-Petteri Mäkinen; Anwar Mulugeta; Jisu Shin; Terry Boyle; Elina Hyppönen; Sang Hong Lee
Journal:  Commun Biol       Date:  2022-06-21

5.  Expression profiles and functional prediction of long non-coding RNAs LINC01133, ZEB1-AS1 and ABHD11-AS1 in the luminal subtype of breast cancer.

Authors:  Sepideh Mehrpour Layeghi; Maedeh Arabpour; Abbas Shakoori; Mohammad Mehdi Naghizadeh; Yaser Mansoori; Javad Tavakkoly Bazzaz; Rezvan Esmaeili
Journal:  J Transl Med       Date:  2021-08-26       Impact factor: 5.531

6.  The Thyroid Hormone Receptor-RUNX2 Axis: A Novel Tumor Suppressive Pathway in Breast Cancer.

Authors:  Eric L Bolf; Noelle E Gillis; Michael S Barnum; Caitlin M Beaudet; Grace Y Yu; Jennifer A Tomczak; Janet L Stein; Jane B Lian; Gary S Stein; Frances E Carr
Journal:  Horm Cancer       Date:  2019-12-21       Impact factor: 3.869

7.  Retinoid X receptor gamma (RXRG) is an independent prognostic biomarker in ER-positive invasive breast cancer.

Authors:  Chitra Joseph; Sara Al-Izzi; Mansour Alsaleem; Sasagu Kurozumi; Michael S Toss; Maariya Arshad; Fang Qin Goh; Ibraheem M Alshankyty; Mohammed A Aleskandarany; Simak Ali; Ian O Ellis; Nigel P Mongan; Andrew R Green; Emad A Rakha
Journal:  Br J Cancer       Date:  2019-09-27       Impact factor: 7.640

Review 8.  Leveraging Nuclear Receptors as Targets for Pathological Ocular Vascular Diseases.

Authors:  Pei-Li Yao; Jeremy Peavey; Goldis Malek
Journal:  Int J Mol Sci       Date:  2020-04-21       Impact factor: 5.923

Review 9.  Nuclear Receptors as Potential Therapeutic Targets for Myeloid Leukemia.

Authors:  Pan Pan; Xiao Chen
Journal:  Cells       Date:  2020-08-19       Impact factor: 6.600

10.  Cytoplasmic and Nuclear Forms of Thyroid Hormone Receptor β1 Are Inversely Associated with Survival in Primary Breast Cancer.

Authors:  Wanting Shao; Christina Kuhn; Doris Mayr; Nina Ditsch; Magdalena Kailuweit; Verena Wolf; Nadia Harbeck; Sven Mahner; Udo Jeschke; Vincent Cavaillès; Sophie Sixou
Journal:  Int J Mol Sci       Date:  2020-01-03       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.